Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Essity Restructures in France

Posted on: 31 Jul 18

STOCKHOLM, July 31, 2018 /PRNewswire/ --

Essity is closing a converting facility for retail branded products in Saint-Etienne-du-Rouvray and invests in remaining integrated production facilities in France. The closure is expected during the fourth quarter of 2018. These measures are aligned with the company's strategy to optimize the production footprint to increase cost and capital efficiency and further increase value creation in the Consumer Tissue business area.

The restructuring costs are expected to amount to approximately SEK 480m, of which approximately SEK 430m is expected to be recognized as an item affecting comparability in the third quarter of 2018. The remaining costs are expected to be recognized as an item affecting comparability in 2019. Approximately SEK 320m of the restructuring costs are expected to impact cash flow. Total investments will amount to approximately SEK 210m.

For additional information, please contact:   

Henrik Sjöström,

Media Relations Manager



Johan Karlsson,

Vice President Investor Relations


Editor's Details

Mike Wood

Last updated on: 31/07/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.